Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Current practices, organizational structures, technologies and challenges in developing atmps: A survey by dare-NL, nxtgen hightech, T2EVOLVE and ctiwp of EBMT - a gocart-coalition initiative

Anil Deshantri, Simone Punt, Ganesh Ramesh, Aiko Ballardini, Emma Martinez Sanchez, Jesus Fernandez-Sojo, Sergi Querol Giner, Zsolt Sebestyen, Carmen Sanges, Michael Hudecek, Ruud Das, Florent Malard, Jorinde Hoogenboom, Jarl Mooyaart, Annalisa Ruggeri, Trudy Straetemans, Jurgen Kuball

Blood (2025) 146 (Supplement 1): 5961.

https://doi.org/10.1182/blood-2025-5961

Published: 2025

Journal Articles

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

Blood (2025) 146 (Supplement 1): 2450.

https://doi.org/10.1182/blood-2025-2450

Published: 2025

Journal Articles

MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Results from the ARES phase III trial

Florent Malard, Jaime Sanz, Clemence Mediavilla, Lucia Lopez-Corral, Alexander Schauwvlieghe, Marc Bernard, Michael Loschi, Sylvie François, Francesca Bonifazi, Daniela Heidenreich, Marion Bruelle, Behzad Kharabi Masouleh, Emilie Plantamura, Ernst Holler, Mohamad Mohty

Blood (2025) 146 (Supplement 1): 817.

https://doi.org/10.1182/blood-2025-817

Published: 2025

Journal Articles

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Blood (2025) 146 (Supplement 1): 130.

https://doi.org/10.1182/blood-2025-130

Published: 2025

Journal Articles

Impact of baseline suvmax in untreated high-tumor-burden follicular lymphoma

Ikram Bouguern, Zora Marjanovic, Elise Corre, Laure Ricard, Fazia Kaoui, Zoe Van de Wyngaert, Paul Coppo, Mohamad Mohty, Florent Malard, Nicolas Stocker

Blood (2025) 146 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2025-3604

Published: 2025

Journal Articles

Antibiotics: bad bugs for CAR-T cells?

Florent Malard, Mohamad Mohty

Blood (2025) 145 (8): 787–788.

https://doi.org/10.1182/blood.2024027102

Published: 2025

Journal Articles

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Blood (2024) 144 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2024-206867

Published: 2024

Journal Articles

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Laura G.M. Daenen, Lotte Van Der Wagen, Edouard F. Bonneville, Lucia Lopez Corral, Laimonas Griskevicius, Martin Bornhäuser, Yves Beguin, Maija Itala-Remes, Jorinde D. Hoogenboom, Liesbeth C. de Wreede, Florent Malard, Christian Chabannon, Francesco Dazzi, Annalisa Ruggeri, Jurgen Kuball

Blood (2024) 144 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2024-201358

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 3456.

https://doi.org/10.1182/blood-2024-211010

Published: 2024

Journal Articles

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

Blood (2024) 144 (16): 1747–1751.

https://doi.org/10.1182/blood.2024024351

Published: 2024

Includes: Supplemental data

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Potential future direction of measurable residual disease evaluation in multiple myeloma

Mohamad Mohty, Hervé Avet-Loiseau, Florent Malard, Jean-Luc Harousseau

Blood (2023) 142 (18): 1509–1517.

https://doi.org/10.1182/blood.2023020284

Published: 2023

Includes: Supplemental data

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2023-188655

Published: 2023

Journal Articles

A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating the Efficacy and Safety of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy in Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: The Phoebus Trial

Florent Malard, Myriam Labopin, Ernst Holler, Joël Doré, Emilie Plantamura, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4947.

https://doi.org/10.1182/blood-2023-185639

Published: 2023

Journal Articles

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Blood (2023) 142 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2023-185945

Published: 2023

Journal Articles

IL-22, a new beacon in gastrointestinal aGVHD

Mohamad Mohty, Florent Malard

Blood (2023) 141 (12): 1369–1370.

https://doi.org/10.1182/blood.2022018934

Published: 2023

Journal Articles

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Florent Malard, Sylvain Thepot, Thomas Cluzeau, Martin Carre, Delphine Lebon, Cyrielle Gasc, Juliette Jouve, Benoit Levast, Emilie Plantamura, Emmanuel Prestat, Antoine Sabourin, Joel Doré, Mohamad Mohty, Christian Recher

Blood (2022) 140 (Supplement 1): 6215–6217.

https://doi.org/10.1182/blood-2022-165938

Published: 2022

Journal Articles

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Moniek de Witte, Jorinde Hoogenboom, Jarl Mooyaart, Christian Chabannon, Florent Malard, Annalisa Ruggeri, Jurgen Kuball

Blood (2022) 140 (Supplement 1): 4741–4742.

https://doi.org/10.1182/blood-2022-157422

Published: 2022

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 4668–4670.

https://doi.org/10.1182/blood-2022-162682

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Current practices, organizational structures, technologies and challenges in developing atmps: A survey by dare-NL, nxtgen hightech, T2EVOLVE and ctiwp of EBMT - a gocart-coalition initiative

MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Results from the ARES phase III trial

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Impact of baseline suvmax in untreated high-tumor-burden follicular lymphoma

Antibiotics: bad bugs for CAR-T cells?

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Potential future direction of measurable residual disease evaluation in multiple myeloma

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating the Efficacy and Safety of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy in Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: The Phoebus Trial

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

IL-22, a new beacon in gastrointestinal aGVHD

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only